Fundsmith 13F: Cuts Catalyst Pharmaceuticals (CPRX) Stake by $79M

Fundsmith Trims Catalyst Pharmaceuticals Stake

Fundsmith slashed its position in Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) by 74.8% during the most recent reporting period, according to the firm's latest Form 13F filing with the Securities and Exchange Commission. The investment fund sold 2,518,920 shares of the biotechnology company, leaving it with 844,887 shares. The remaining position was valued at approximately $26.5 million at the end of the quarter. This filing reflects the fund's holdings as of the reporting date and may not represent its current portfolio.

Fundsmith, founded by veteran investor Terry Smith, is known for its high-conviction, long-term approach to investing. The firm typically targets high-quality businesses with strong return on capital and holds them for years. However, this major reduction in Catalyst Pharmaceuticals is part of a broader trend of position adjustments for the fund. In recent quarters, Fundsmith has been actively pruning its portfolio, completely exiting positions in Graco Inc., Choice Hotels International, and Exponent, Inc., while also trimming its stakes in other mid-cap firms like Doximity and Napco Security Technologies.

Catalyst Pharmaceuticals Stock Performance

On Saturday, Catalyst Pharmaceuticals shares were priced at $31.36. The stock has been trading in a strong upward channel, hovering just below its 52-week high of $32.56 and well above its 52-week low of $19.05. The company's shares are also trading comfortably above their 200-day moving average of $25.90, which is a common indicator of a long-term upward trend. Catalyst has a market capitalization of $3.85 billion and trades at a price-to-earnings ratio of 18.2, reflecting a reasonable valuation relative to its biotech peers.

Recent Earnings and Financial Health

Catalyst Pharmaceuticals has demonstrated solid financial health. The company generated $596.96 million in revenue over the last twelve months, achieving a revenue growth rate of 5.6%. Catalyst is highly profitable, boasting a net profit margin of 37.1% and an impressive return on equity of 24.5%. The company's balance sheet is exceptionally strong, with a current ratio of 7.1 and a quick ratio of 6.7, showing it has plenty of liquid assets to cover short-term obligations.

Focusing on Rare Diseases

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and sells therapies for rare diseases. The company is best known for Firdapse, which treats a rare autoimmune disorder called Lambert-Eaton myasthenic syndrome. It also markets Fycompa for epilepsy and Agamree for Duchenne muscular dystrophy. Managing a small portfolio of specialized drugs has allowed the company to maintain high margins, though the loss of a major institutional backer like Fundsmith will be a key storyline for investors to track in upcoming regulatory filings.